No it is not good, but what are we to do? We have to move forward right? That is all
I am saying. I realize this was potentially huge, but it is gone, so rather than state that it is all doom and gloom, I prefer to move forward and the company will do the same thing. DO you think that they are not looking for opportunities to acquire from others whether it be companies or products? They are not going to sit still, have faith.
BTW who stated it was a great drug and everyone had been the chosen ones to lead the pack? Have you seen what the FDA has been doing lately....no drug is a slam dunk.
Im not the OP, but he does have a point. From a revenue perspective, Dalcetrapib is/was the biggest product in the Roche pipeline. From a professional opportunity perspective, its not even close; from DMs, to Reps, to marketing, Even RSDs, Sales Ops, you name it. This drug was so huge, it would have meant opportunities to hire/promote 150-200 DMs, 1500-2000 sales reps, maybe a dozen RSDs; the ripple effect of this product being launched would have been huge. From an opportunity standpoint, there is nothing on the near term horizon, at Roche, that is even a fraction of Dal's.
The OP was not being negative, he was being real. There are hundreds of former colleagues, that were let go over the last 18 months, he hopes (in the dire pharma environment) hinged on these Dal opportunities. There are many people in Roche right now, who jobs revolve around launching Dal (marketing, sales ops, r&D, etc) who will clearly lose their jobs over this news.
With all due respect, Its ok to be optimistic, but blind optimism in the face of an overwhelming undeniable reality is not really optimism, its called "being oblivious". This indeed is a horrible to for Roche. Between Tasp, and dal, there are two products that had to be pulled, that would have contributed 40% of Roche revenues annually. THIS IS NOT GOOD AT ALL![/QUOTE]